Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02692391 · ClinicalTrials.gov registry record · Phase 3

A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis

A Phase 3 study, sponsored by University of Pittsburgh.

Completed
Registry status
Phase 3
Development phase
42
Enrollment target

NCT02692391: Completed Phase 3 study, sponsored by University of Pittsburgh.

NCT02692391 is a Phase 3 study that has completed, run by University of Pittsburgh. The registered enrollment target is 42 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02692391, a Phase 3 study, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
Phase 3
Development phase
42 participants
Enrollment target

Study Summary

This is a randomized, double-blind, placebo-controlled pilot trial seeking to evaluate the efficacy of rectal indomethacin in abrogating systemic inflammation and subsequently organ failure and mortality in patients with AP and positive SIRS score.

Primary Outcome

SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension and white blood count) that directly reflect the underlying inflammatory response. A lower change in SIRS score (negative number) indicates a better outcome (less inflammation).

Interventions

  • DRUG Placebo
  • DRUG Indomethacin

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2013-07
Est. Completion 2019-12-30
Phase Phase 3
University of Pittsburgh

1,238 total trials

What the finished NCT02692391 record still lists

NCT02692391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02692391 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02692391 about?

NCT02692391 is a clinical study titled "A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis". This is a randomized, double-blind, placebo-controlled pilot trial seeking to evaluate the efficacy of rectal indomethacin in abrogating systemic inflammation and subsequently organ failure and mortality in patients with AP and positive SIRS score.

What is the current status of trial NCT02692391?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2013-07. Estimated completion is 2019-12-30.

What interventions are being tested in trial NCT02692391?

The interventions under investigation include: Placebo (DRUG), Indomethacin (DRUG).

Who is sponsoring clinical trial NCT02692391?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02692391's enrollment target sits among peer trials

42 1877th of 2000 higher than 124 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02692391, the US trial registry maintained by the National Library of Medicine. NCT02692391 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.